Accellix

@Accellix (a bioMérieux company) will be in London for the Advanced Therapies Congress2026 (#adtherapies26). Join us for this must attend presentation Tuesday March 17 | 2:35–2:55 PM | Cell Therapy Track

📍 𝗥𝗘𝗠𝗜𝗡𝗗𝗘𝗥: If you’re at #ATW26, join us for these must-attend sessions happening today and drop by booth #637 to meet the Accellix team to learn more!

We're excited to connect at #ATW26 with cell therapy developers and CDMOs focused on automated QC for cell therapy manufacturing, point-of-use immunophenotyping & reducing variability & manual burden in GMP workflows. Join @accellix team at the sessions throughout the week:

U.K. biotech Ikarovec is partnering with @VectorBuilder to progress an eye disease gene therapy that could be administered in a doctor’s office. A one-time injectable, IKAR-003 is in preclinical development to prevent the progression of intermediate AMD. fiercebiotech.com/biotech/uk-bio…

Earlier this week, the FDA released new guidance introducing greater flexibility in manufacturing and control (CMC) expectations for cell and gene therapies towards accelerating innovation in the field. clinicaltrialsarena.com/news/fda-incre…

@Accellix 𝗶𝘀 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝗸𝗶𝗰𝗸𝘀𝘁𝗮𝗿𝘁 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿 𝗮𝘁 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗪𝗲𝗲𝗸 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗦𝗮𝗻 𝗗𝗶𝗲𝗴𝗼! From posters and presentations to an engaging panel discussion, we're excited to contribute to conversations shaping the field.

Despite a year of uncertainty across the biopharma industry, a surge of activity in December 2025 brought the total number of @US_FDA to 55 drug products. Of these, 46 were novel drug approvals, compared with 55 in 2023 and 50 in 2024. fiercepharma.com/pharma/2025-dr…

Several cell and gene therapies are nearing potential @US_FDA decisions. With Prescription Drug User Fee Act (PDUFA) dates on the calendar, a and several recent BLA submissions, the coming months could help set the tone for CGTs in 2026. cgtlive.com/view/fda-decis…

Closing out 2025 with an @US_FDA approval: @OmerosCorp's Yartemlea is the 1st-ever treatment for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA), an complication that can occur in ~56% of allogeneic transplant patients. fiercepharma.com/pharma/omeros-…

accellix would like to extend our warmest holiday wishes to you and yours. Thank our team, clients, and partners who make our work truly meaningful. Wishing you a joyful holiday season filled with peace, and health. We look forward to collaborating in the new year.

@Kyverna_Tx announced positive Phase 2 results for KYV-101 (miv-cel), an investigational CAR-T therapy for stiff person syndrome, a rare and progressive autoimmune disease with no currently approved treatments. biopharmadive.com/news/kyverna-s…

#TechTuesday: @accellix and @Excellos_Corp provide a CDMO perspective for how the Accellix Platform is advantageous across the allogeneic cell therapy development and manufacturing workflow. Watch the full presentation here:  accellix.com/webinar/advant…

New HSC-based gene therapy to treat Wiskott-Aldrich syndrome (WAS) is making headlines as the first FDA-approved therapy developed by a non-profit organization—a milestone for patients and for the field. fiercepharma.com/pharma/italian….

@accellix is attending the 3rd Annual Cell Therapy for Autoimmune Disease Summit in Philadelphia. We’re looking forward to the discussions, collaboration, and fresh perspectives that will help accelerate therapeutic progress.

Accellix is attending the ASH Annual Meeting in Orlando this December 6 - 9 for the first time! Meet us at booth #110 to learn how automated immunophenotyping using the @accellix platform can strengthen manufacturing consistency and reduce process risk for blood-based therapies.

@Accellix will be at the Cell Therapy Analytical Development Summit in Boston next week! Join us on Tuesday, December 2nd for these must-attend sessions! #CTAD2025 #Leukapheresis #Characterization #FlowCytometry #Potency #CellTherapy #CellandGeneTherapy

@accellix was recently featured in @AABB Biotherapies Pavilion Participant Spotlight, a Q&A interview highlighting our mission and the role automated flow cytometry plays in advancing the development and manufacture of cell therapies: aabb.org/blood-biothera…

#TechTuesday: This four minute video by the Leukopak Lady describes how the @Accellix automated flow cytometry platform can be used by collection centers at the point of collection to generate leukopak characterization data: accellix.com/video/leukopak…

ICYMI: Last week’s BioPharma webinar with speakers from Tigen Pharma, @CRiverLabs , and @Accellix is now available to watch on demand. #webinar_embed" target="_blank" rel="nofollow noopener">biopharmawebinars.com/webinars/poten… #potency #celltherapy #cellandgenetherapy #characterization #leukapheresis

A new "plausible mechanism" pathway introduced by the @US_FDA could redefine how N-of-1, ultra-rare, & pediatric therapies are approved. For families dealing with ultra-rare conditions, this change could be life-saving. fiercebiotech.com/biotech/fdas-n…